Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
Titel:
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
Auteur:
Gervais, R. Ducolone, A. Breton, J.-L. Braun, D. Lebeau, B. Vaylet, F. Debieuvre, D. Pujol, J.-L. Tredaniel, J. Clouet, P. Quoix, E.